全身MRI与标准影像路径对新诊断非小细胞肺癌转移灶的诊断准确性:前瞻性Streamline L试验
Streamline L为前瞻性多中心试验,纳入353例新诊断、胸部CT示潜在可根治(≤IIIb期)的NSCLC患者,比较WB-MRI与标准分期路径对转移灶的诊断准确性及效率。WB-MRI分期完成时间更短(13天 vs 19天,差6天),人均费用更低(317英镑 vs 620英镑)。
要点
- WB-MRI与标准路径对NSCLC转移灶的敏感性、特异性无显著差异。
- WB-MRI分期完成时间较标准路径缩短6天,人均费用更低。
- 两种路径与多学科团队最终治疗决策的一致率分别为98%与99%。
核心结论
- WB-MRI分期路径诊断准确性与标准路径相似,并可缩短分期时间、降低费用。
研究设计与样本
- 前瞻性、多中心试验,在英国16家医院开展,筛查976例,招募353例,187例完成试验。
- 纳入18岁及以上、胸部CT示潜在可根治(IIIb期或以下)的新诊断NSCLC患者。
- 排除严重系统性疾病、妊娠、MRI禁忌或非NSCLC组织学类型者。
- WB-MRI结果在标准分期完成及首次治疗决策制定前对多学科团队设盲。
主要发现
- 完成试验的187例中52例(28%)基线存在转移。
- 与多学科团队最终治疗决策一致率:WB-MRI 98%,标准路径99%。
- 分期完成时间WB-MRI 13天(95%CI 12-14),标准路径19天(95%CI 17-21),差异6天(95%CI 4-8);所需检查数WB-MRI 1次(95%CI 1-1),标准路径1次(95%CI 1-2);人均费用WB-MRI 317英镑(95%CI 273-361),标准路径620英镑(95%CI 574-666)。
临床怎么用
- WB-MRI可作为新诊断潜在可根治NSCLC患者分期路径的替代选择,准确性相似且更高效。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, cost, and effect on treatment decisions are unknown. We aimed to prospectively compare the diagnostic accuracy and efficiency of WB-MRI-based staging pathways with standard pathways in NSCLC. METHODS: The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients were 18 years or older, with newly diagnosed NSCLC that was potentially radically treatable on diagnostic chest CT (defined as stage IIIb or less). Exclusion criteria were severe systemic disease, pregnancy, contraindications to MRI, or histologies other than NSCLC. Patients underwent WB-MRI, the result of which was withheld until standard staging investigations were complete and the first treatment decision made. The multidisciplinary team recorded its treatment decision based on standard investigations, then on the WB-MRI staging pathway (WB-MRI plus additional tests generated), and finally on all tests. The primary outcome was difference in per-patient sensitivity for metastases between standard and WB-MRI staging pathways against a consensus reference standard at 12 months, in the per-protocol population. Secondary outcomes were difference in per-patient specificity for metastatic disease detection between standard and WB-MRI staging pathways, differences in treatment decisions, staging efficiency (time taken, test number, and costs) and per-organ sensitivity and specificity for metastases and per-patient agreement for local T and N stage. This trial is registered with the International Standard Randomised Controlled Trial registry, number ISRCTN50436483, and is complete. FINDINGS: Between Feb 26, 2013, and Sept 5, 2016, 976 patients were screened for eligibility. 353 patients were recruited, 187 of whom completed the trial; 52 (28%) had metastasis at baseline. Pathway sensitivity was 50% (95% CI 37-63) for WB-MRI and 54% (41-67) for standard pathways, a difference of 4% (-7 to 15, p=0·73). No adverse events related to imaging were reported. Specificity did not differ between WB-MRI (93% [88-96]) and standard pathways (95% [91-98], p=0·45). Agreement with the multidisciplinary team's final treatment decision was 98% for WB-MRI and 99% for the standard pathway. Time to complete staging was shorter for WB-MRI (13 days [12-14]) than for the standard pathway (19 days [17-21]); a 6-day (4-8) difference. The number of tests required was similar WB-MRI (one [1-1]) and standard pathways (one [1-2]). Mean per-patient costs were £317 (273-361) for WBI-MRI and £620 (574-666) for standard pathways. INTERPRETATION: WB-MRI staging pathways have similar accuracy to standard pathways, and reduce the staging time and costs. FUNDING: UK National Institute for Health Research.
引用
- Taylor SA, Mallett S, Ball S, et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respir Med. 2019. PMID: 31080129. doi:10.1016/S2213-2600(19)30090-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。